• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)

    2/14/23 4:06:08 PM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLU alert in real time by email
    SC 13G/A 1 formsc13ga.htm

      

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.1)*

     

    BELLUS Health Inc.
    (Name of Issuer)

     

    Common Shares, no par value
    (Title of Class of Securities)

     

    07987C204
    (CUSIP Number)

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

     

     

     

    CUSIP No.  07987C204 SCHEDULE 13G  

     

             
    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    5,303,557*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    5,303,557*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,303,557*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.2%*

    12

    TYPE OF REPORTING PERSON

     

    IA

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No.  07987C204 SCHEDULE 13G  

     

             
    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    5,303,557*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    5,303,557*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,303,557*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.2%*

    12

    TYPE OF REPORTING PERSON

     

    OO 

     

    *See Item 4 for additional information.

     

     

     

      

    CUSIP No. 07987C204 SCHEDULE 13G  

     

    Item 1. (a) Name of Issuer
       
      BELLUS Health Inc. (the “Issuer”)
       
    Item 1. (b) Address of Issuer’s Principal Executive Offices
       
      275 Armand-Frappier Blvd., Laval, Quebec H7V 4A7, Canada
       
    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
       
      This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.
       
    Item 2. (d) Title of Class of Securities
       
      Common Shares, no par value (the “Common Stock”)
       
    Item 2. (e) CUSIP No.:
       
      07987C204
       
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:
       
      N/A

     

     

     

     

    CUSIP No. 07987C204 SCHEDULE 13G  

     

    Item 4. Ownership
       
      As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:
       
      (a) Amount Beneficially Owned: 5,303,557 *
      (b) Percent of Class: 4.2%*
      (c) Number of Shares as to which such person has:

     

        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 5,303,557 *
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 5,303,557 *

     

      As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:
       
      (a) Amount Beneficially Owned: 5,303,557 *
      (b) Percent of Class: 4.2%*
      (c) Number of Shares as to which such person has:

     

        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 5,303,557 *
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 5,303,557 *

     

    *The Firm is the investment manager to Commodore Master. As of December 31, 2022, the Firm may be deemed to beneficially own an aggregate of 5,303,557 shares of Common Stock of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 125,792,916 shares of Common Stock reported as issued and outstanding in the Issuer’s prospectus supplement to Form F-10 filed with the Securities and Exchange Commission on November 14, 2022.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person
       
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
       
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group
       
      Not Applicable.
       
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

       

    Exhibit Index

     

      1. Joint Filing Agreement dated as of February 14, 2022, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on February 14, 2022).

      

     

     

      

    CUSIP No. 07987C204 SCHEDULE 13G  

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

    Commodore Capital LP  
       
    By: /s/ Michael Kramarz  
    Michael Kramarz, Managing Partner  
       
    Commodore Capital Master LP  
       
    By: /s/ Michael Kramarz  
    Michael Kramarz, Authorized Signatory  

     

     

     

    Get the next $BLU alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BLU

    DatePrice TargetRatingAnalyst
    4/19/2023Outperform → Sector Perform
    RBC Capital Mkts
    2/24/2022$14.00 → $16.00Buy
    HC Wainwright & Co.
    12/13/2021$12.00 → $20.00Outperform
    Evercore ISI Group
    12/7/2021$9.00 → $11.00Outperform
    RBC Capital
    10/18/2021$8.00 → $9.00Outperform
    RBC Capital
    9/14/2021$10.00 → $14.00Buy
    HC Wainwright & Co.
    7/29/2021$9.00Buy
    BTIG Research
    More analyst ratings

    $BLU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

      LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R

      6/28/23 10:57:00 AM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders

      BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced the positive outcome of the BELLUS shareholders ("Shareholders") vote at this morning's special meeting of the Shareholders (the "Special Meeting") held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a corporation existing under the laws of Canada and a wholly-owned subsidiary of GSK plc (NYSE:GSK, LSE: GSK))) ("GSK"), will acquire, for a purchase price of US$14.75 in cash per share, all of the issued and outstanding common shares of BELLUS (the

      6/16/23 1:50:00 PM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition

      Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a co

      5/16/23 5:01:00 PM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BELLUS Health Inc.

      SC 13G - BELLUS Health Inc. (0001259942) (Subject)

      1/30/24 10:56:14 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)

      SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)

      8/14/23 5:01:58 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BELLUS Health Inc.

      SC 13G - BELLUS Health Inc. (0001259942) (Subject)

      3/30/23 4:05:24 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLU
    SEC Filings

    See more
    • SEC Form 15-12G filed by BELLUS Health Inc.

      15-12G - BELLUS Health Inc. (0001259942) (Filer)

      7/10/23 8:00:11 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by BELLUS Health Inc.

      S-8 POS - BELLUS Health Inc. (0001259942) (Filer)

      6/28/23 5:20:23 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by BELLUS Health Inc.

      S-8 POS - BELLUS Health Inc. (0001259942) (Filer)

      6/28/23 4:57:20 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BELLUS Health downgraded by RBC Capital Mkts

      RBC Capital Mkts downgraded BELLUS Health from Outperform to Sector Perform

      4/19/23 8:02:26 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on BELLUS Health with a new price target

      HC Wainwright & Co. reiterated coverage of BELLUS Health with a rating of Buy and set a new price target of $16.00 from $14.00 previously

      2/24/22 6:21:58 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI Group reiterated coverage on BELLUS Health with a new price target

      Evercore ISI Group reiterated coverage of BELLUS Health with a rating of Outperform and set a new price target of $20.00 from $12.00 previously

      12/13/21 10:40:28 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLU
    Leadership Updates

    Live Leadership Updates

    See more
    • OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

      NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

      1/4/23 8:00:00 AM ET
      $BLU
      $GKOS
      $INSP
      $NTLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors

      LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas. “Bill is a biopharmaceutical veteran with a proven drug development track record, including the approval of several drugs within the respiratory field,” c

      3/24/21 7:00:00 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLU
    Financials

    Live finance-specific insights

    See more
    • Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

      LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R

      6/28/23 10:57:00 AM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

      Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ≤ 0.005) BLU-5937 was well-tolerated with a low rate of taste-related adverse events (≤6.5%); treatment emergent adverse event profile comparable to placebo Company also provides an update on its P2X3 pipeline and BLU-5937 Phase 2a trial for the treatment of chronic pruritus Company to host conference call and webcast at 8:00 a.m. ET BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC"

      12/13/21 7:00:00 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care